Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.
about
Clinical use of pasireotide for Cushing's disease in adultsThe Treatment of Cushing's Disease.Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegalyUpdate on medical treatment for Cushing's disease.Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trialUp-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.Pituitary-directed medical therapy in Cushing's disease.Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitroThe role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.Effectiveness of low-dose pasireotide in a patient with Cushing's disease: antiproliferative effect and predictivity of a short pasireotide suppression test.Pituitary-Directed Therapies for Cushing's Disease.
P2860
Q26858933-907A29D5-8532-4CCE-B1C7-0F5AA370BF3AQ27010590-31D15C11-E7BF-4230-AE97-990EDDCDA99EQ28069603-17F35F12-F1E0-481A-9DE0-B1F67B5FBB42Q33802284-93FC079C-E63E-43BF-AEF4-9F220BA21487Q33840655-C80BA884-089F-42ED-BE6E-A518FA364AC9Q38222170-BAED9E96-3753-48E3-8E8D-17F3C5C8FF86Q38334659-D9FACC58-FAB8-422F-A828-E9FF96AF05BFQ38683309-905A05B1-7519-4FF3-9A7D-D0A6DE50E2A8Q38912799-442311FA-D9DB-4FE7-B69F-9BDA9D579A67Q41548629-5DC4632F-CDCC-48AE-8141-45BACD2F447DQ41698329-EE5853F1-9D03-47D0-94F3-340F0EA3CCF0Q42911830-9151D180-F343-4621-BA81-81A2EFCEED78Q54961209-250AFAFD-1449-4D1A-9F40-8FE6C5127BD5
P2860
Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pasireotide monotherapy in Cus ...... extension of phase III Trial.
@ast
Pasireotide monotherapy in Cus ...... extension of phase III Trial.
@en
type
label
Pasireotide monotherapy in Cus ...... extension of phase III Trial.
@ast
Pasireotide monotherapy in Cus ...... extension of phase III Trial.
@en
prefLabel
Pasireotide monotherapy in Cus ...... extension of phase III Trial.
@ast
Pasireotide monotherapy in Cus ...... extension of phase III Trial.
@en
P2093
P2860
P1433
P1476
Pasireotide monotherapy in Cus ...... extension of phase III Trial.
@en
P2093
André Lacroix
Hugues Beauregard
Isabelle Bourdeau
Jessica MacKenzie Feder
Louis-Georges Ste-Marie
Sophie Vallette
P2860
P2888
P304
P356
10.1007/S11102-013-0539-4
P577
2014-12-01T00:00:00Z